Implications of genomic instability in the diagnosis and treatment of breast cancer

Expert Review of Molecular Diagnostics

Volumn 11, Issue 4, 2011, Pages 445-453

  Wiechec, Emilia ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

breast cancer; chromosomal aberrations; diagnosis; genomic instability; prognosis; treatment

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; APC PROTEIN; ATM PROTEIN; AURORA A KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FRAGILE HISTIDINE TRIAD PROTEIN; GELDANAMYCIN; HISTONE H3; MYC PROTEIN; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MAD2; PROTEIN MDM2; PROTEIN P53; PROTEIN RGSL2; PROTEIN WWOX; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOBLASTOMA PROTEIN; RGS PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENOME; GENOMIC INSTABILITY; HISTONE ACETYLATION; HUMAN; POINT MUTATION; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMANS;

EID: 79955749248     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.21     Document Type: Review

References (90)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2(3), 133-140 (2001). (Pubitemid 33585924)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
3. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
4. Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J. Biol. 7(2), 6 (2008).
5. Wiechec E, Hansen LL. The effect of genetic variability on drug response in conventional breast cancer treatment. Eur. J. Pharmacol. 625(1-3), 122-130 (2009).
6. Choi JY, Nowell SA, Blanco JG, Ambrosone CB. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 7(4), 613-624 (2006). (Pubitemid 43891417)
7. Levitt NC, Hickson ID. Caretaker tumour suppressor genes that defend genome integrity. Trends Mol. Med. 8(4), 179-186 (2002). (Pubitemid 34297091)
8. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 313(Pt 1), 17-29 (1996). (Pubitemid 26013419)
9. Feig DI, Reid TM, Loeb LA. Reactive oxygen species in tumorigenesis. Cancer Res. 54(7 Suppl.), 1890s-1894s (1994). (Pubitemid 24132140)
10. Anderson GR, Stoler DL, Brenner BM. Cancer: the evolved consequence of a destabilized genome. Bioessays 23(11), 1037-1046 (2001).
11. Eyfjord JE, Bodvarsdottir SK. Genomic instability and cancer: networks involved in response to DNA damage. Mutat. Res. 592(1-2), 18-28 (2005). (Pubitemid 41714040)
12. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
13. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res. 69(10), 4116-4124 (2009).
14. Jonsson G, Staaf J, Vallon-Christersson J et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 12(3), R42 (2010).
15. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5(1), 5-23 (2011).
16. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101(10), 736-750 (2009).
17. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11(16), 5678-5685 (2005). (Pubitemid 41170290)
18. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 52(1), 108-118 (2008). (Pubitemid 350265179)
19. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13(15 Pt 1), 4429-4434 (2007). (Pubitemid 47219710)
20. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 9(Suppl. 2), S73-S81 (2009).
21. Shin BK, Lee Y, Lee JB, Kim HK, Cho SJ, Kim A. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncol. Rep. 19(3), 617-625 (2008). (Pubitemid 351330426)
22. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12(5), R68 (2010).
23. Taube JH, Herschkowitz JI, Komurov K et al. Core epithelial-to- mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. USA 107(35), 15449-15454 (2010).
24. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
25. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 34(Pt 5), 633-645 (2006). (Pubitemid 44796392)
26. Linger RJ, Kruk PA. BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. FEBS J. 277(15), 3086-3096 (2010).
27. Holstege H, Horlings HM, Velds A et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 10, 654 (2010).
28. Saal LH, Gruvberger-Saal SK, Persson C et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 40(1), 102-107 (2008).
29. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364(3), 205-214 (2011).
30. Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin. Cancer Res. 5(4), 839-844 (1999). (Pubitemid 29180836)
31. Lacroix-Triki M, Lambros MB, Geyer FC, Suarez PH, Reis-Filho JS, Weigelt B. Absence of microsatellite instability in mucinous carcinomas of the breast. Int. J. Clin. Exp. Pathol. 4(1), 22-31 (2010).
32. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining 'chromosomal instability'. Trends Genet. 24(2), 64-69 (2008).
33. Pellman D. Cell biology: aneuploidy and cancer. Nature 446(7131), 38-39 (2007). (Pubitemid 46348036)
34. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr. Opin. Cell Biol. 18(6), 658-667 (2006). (Pubitemid 44692476)
35. Tang YC, Williams BR, Siegel JJ, Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell 144(4), 499-512 (2011).
36. Huang HE, Chin SF, Ginestier C et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/ heregulin gene. Cancer Res. 64(19), 6840-6844 (2004). (Pubitemid 39330987)
37. Cheung AL, Deng W. Telomere dysfunction, genome instability and cancer. Front. Biosci. 13, 2075-2090 (2008). (Pubitemid 351589236)
38. Lo AW, Sabatier L, Fouladi B, Pottier G, Ricoul M, Murnane JP. DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. Neoplasia 4(6), 531-538 (2002). (Pubitemid 35417077)
39. Gruhne B, Kamranvar SA, Masucci MG, Sompallae R. EBV and genomic instability - a new look at the role of the virus in the pathogenesis of Burkitt's lymphoma. Semin. Cancer Biol. 19(6), 394-400 (2009).
40. Bailey SM, Murnane JP. Telomeres, chromosome instability and cancer. Nucleic Acids Res. 34(8), 2408-2417 (2006). (Pubitemid 43985678)
41. Poonepalli A, Banerjee B, Ramnarayanan K, Palanisamy N, Putti TC, Hande MP. Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer. Genes Chromosomes Cancer 47(12), 1098-1109 (2008).
42. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 358(13), 1409-1411 (2008). (Pubitemid 351468442)
43. Tokunaga E, Okada S, Yamashita N et al. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Breast Cancer DOI: 10.1007/s12282-010-0232-7 (2010) (Epub ahead of print).
44. Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res. 60(14), 3706-3712 (2000). (Pubitemid 32204555)
45. Wiechec E, Overgaard J, Hansen LL. A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer 47(9), 766-780 (2008).
46. Arun B, Kilic G, Yen C et al. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol. Biomarkers Prev. 14(7), 1681-1685 (2005). (Pubitemid 40995079)
47. Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX - the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur. J. Surg. Oncol. 32(2), 153-157 (2006). (Pubitemid 43257115)
48. McClelland SE, Burrell RA, Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 8(20), 3262-3266 (2009).
49. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38(9), 1043-1048 (2006). (Pubitemid 44325930)
50. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control 20(9), 1539-1550 (2009).
51. Daskalos A, Nikolaidis G, Xinarianos G et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int. J. Cancer 124(1), 81-87 (2009).
52. Elsheikh SE, Green AR, Rakha EA et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69(9), 3802-3809 (2009).
53. Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br. J. Cancer 97(1), 1-5 (2007). (Pubitemid 47012099)
54. Bediaga NG, Acha-Sagredo A, Guerra I et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 12(5), R77 (2010).
55. Holm K, Hegardt C, Staaf J et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12(3), R36 (2010).
56. Hicks J, Krasnitz A, Lakshmi B et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 16(12), 1465-1479 (2006). (Pubitemid 44878486)
57. Bergamaschi A, Kim YH, Wang P et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45(11), 1033-1040 (2006). (Pubitemid 44435537)
58. Zhou H, Kuang J, Zhong L et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20(2), 189-193 (1998). (Pubitemid 28455454)
59. Lingle WL, Lukasiewicz K, Salisbury JL. Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv. Exp. Med. Biol. 570, 393-421 (2005). (Pubitemid 47413181)
60. Yildirim-Assaf S, Coumbos A, Hopfenmuller W, Foss HD, Stein H, Kuhn W. The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer. J. Clin. Pathol. 60(6), 649-655 (2007). (Pubitemid 46975219)
61. Tutt A, Gabriel A, Bertwistle D et al. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9(19), 1107-1110 (1999). (Pubitemid 29504480)
62. Salisbury JL, D'Assoro AB, Lingle WL. Centrosome amplification and the origin of chromosomal instability in breast cancer. J. Mammary Gland Biol. Neoplasia 9(3), 275-283 (2004). (Pubitemid 39545744)
63. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 274(5285), 246-248 (1996).
64. Choi YH, Ahn JH, Kim SB et al. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann. Oncol. 20(8), 1337-1343 (2009).
65. Chumsri S, Jeter S, Jacobs LK et al. Pathologic complete response to preoperative sequential doxorubicin/ cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin. Breast Cancer 10(1), 40-45 (2010).
66. Yao L, Liu Y, Li Z et al. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann. Oncol. DOI: 10.1093/annonc/ mdq612 (2010) (Epub ahead of print).
67. Visscher DW, Wallis T, Awussah S, Mohamed A, Crissman JD. Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer 18(1), 1-7 (1997). (Pubitemid 27020251)
68. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 5(2), R30-R36 (2003).
69. Gillett C, Fantl V, Smith R et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54(7), 1812-1817 (1994). (Pubitemid 24116192)
70. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57(3), 353-361 (1994). (Pubitemid 24168609)
71. Rudas M, Lehnert M, Huynh A et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin. Cancer Res. 14(6), 1767-1774 (2008). (Pubitemid 351469462)
72. Anzick SL, Kononen J, Walker RL et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277(5328), 965-968 (1997). (Pubitemid 27366683)
73. Alkner S, Bendahl PO, Grabau D et al. AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann. Oncol. 21(2), 238-244 (2010).
74. Ray ME, Yang ZQ, Albertson D et al. Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res. 64(1), 40-47 (2004). (Pubitemid 38114080)
75. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70(5), 2085-2094 (2010).
76. Prentice LM, Shadeo A, Lestou VS et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene 24(49), 7281-7289 (2005). (Pubitemid 41622232)
77. Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177(4), 1647-1656 (2010).
78. Bieche I, Lidereau R. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol. Carcinog. 29(3), 151-158 (2000).
79. Chano T, Ikebuchi K, Tomita Y et al. RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients. PLoS One 5(12), e15737 (2010).
80. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res. 4(1), 5-8 (2002).
81. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 5(6), R217-R222 (2003).
82. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz C. WWOXM, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60(8), 2140-2145 (2000). (Pubitemid 30225175)
83. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect. Prev. 25(3), 292-298 (2001).
84. Ingvarsson S. FHIT alterations in breast cancer. Semin. Cancer Biol. 11(5), 361-366 (2001). (Pubitemid 33016031)
85. Friedrich K, von Heydebreck A, Haroske G et al. Comparative genomic hybridization-based oncogenetic tree model for genetic classification of breast cancer. Anal. Quant. Cytol. Histol. 31(2), 101-108 (2009).
86. Tsuneizumi M, Emi M, Hirano A et al. Association of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy. Cancer Lett. 180(1), 75-82 (2002). (Pubitemid 34242967)
87. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res. 58(10), 2166-2169 (1998). (Pubitemid 28232903)
88. Adeyinka A, Mertens F, Idvall I et al. Different patterns of chromosomal imbalances in metastasising and non-metastasising primary breast carcinomas. Int. J. Cancer 84(4), 370-375 (1999). (Pubitemid 29337122)
89. Muller HM, Widschwendter A, Fiegl H et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 63(22), 7641-7645 (2003). (Pubitemid 37466689)
90. Molina R, Jo J, Filella X et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 19(4A), 2551-2555 (1999). (Pubitemid 29392411)